MCRB Oct 2024 1.000 call
| Previous Close | 0.3500 |
| Open | 0.2000 |
| Bid | 0.0500 |
| Ask | 0.3000 |
| Strike | 1.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.2000 - 0.4500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.9k |
PR NewswireNestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its l
- GlobeNewswire
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement Future Company focus on advancement of SER-155 and other cultivated oral microbiome therapeutics for medically vulnerable patient populations with potential to address large commercial opportunities CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Seres The
Insider MonkeySeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript May 11, 2024 Seres Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is Alex, and I will be your conference operator today. […]
